NCT02105350 2018-02-19
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
University Health Network, Toronto
Phase 1 Withdrawn
University Health Network, Toronto
Cornerstone Pharmaceuticals
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute